264 related articles for article (PubMed ID: 15186710)
1. Preventing and managing antiretroviral drug resistance.
Kuritzkes DR
AIDS Patient Care STDS; 2004 May; 18(5):259-73. PubMed ID: 15186710
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
[TBL] [Abstract][Full Text] [Related]
4. Assessing resistance costs of antiretroviral therapies via measures of future drug options.
Jiang H; Deeks SG; Kuritzkes DR; Lallemant M; Katzenstein D; Albrecht M; DeGruttola V
J Infect Dis; 2003 Oct; 188(7):1001-8. PubMed ID: 14513420
[TBL] [Abstract][Full Text] [Related]
5. Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.
Torti C; Moretti F; Uccelli MC; Tirelli V; Quiros-Roldan E; Gargiulo F; Carosi G
Med Sci Monit; 2003 Apr; 9(4):CS16-9. PubMed ID: 12709675
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral therapy for HIV: drug resistance and sequencing.
Burkle WS
J Assoc Nurses AIDS Care; 2002; 13(1):76-80. PubMed ID: 11828862
[No Abstract] [Full Text] [Related]
7. HIV-1 antiretroviral resistance: scientific principles and clinical applications.
Tang MW; Shafer RW
Drugs; 2012 Jun; 72(9):e1-25. PubMed ID: 22686620
[TBL] [Abstract][Full Text] [Related]
8. Management of HIV infection after triple class failure.
Cossarini F; Spagnuolo V; Gianotti N; Carbone A; Lazzarin A; Castagna A
New Microbiol; 2013 Jan; 36(1):23-39. PubMed ID: 23435813
[TBL] [Abstract][Full Text] [Related]
9. Genotypic resistance tests for the management of the patient failing highly active antiretroviral therapy: the resistance pattern in different biological compartments.
Liuzzi G
Scand J Infect Dis Suppl; 2003; 106():90-3. PubMed ID: 15000595
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 drug resistance testing. IAPAC sessions 2001, July 18-19, 2001 - Chicago.
Simon VA;
IAPAC Mon; 2001 Aug; 7(8):235-7. PubMed ID: 11708276
[No Abstract] [Full Text] [Related]
11. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
[TBL] [Abstract][Full Text] [Related]
12. Genotypic resistance tests for the clinical management of patients with primary HIV infection.
Narciso P; Lazzarin A
Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588
[TBL] [Abstract][Full Text] [Related]
13. A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy.
Newman H; Breunig L; van Zyl G; Stich A; Preiser W
J Clin Virol; 2014 Aug; 60(4):387-91. PubMed ID: 24929754
[TBL] [Abstract][Full Text] [Related]
14. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
[TBL] [Abstract][Full Text] [Related]
15. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study.
Di Giambenedetto S; Bracciale L; Colafigli M; Cattani P; Pinnetti C; Bacarelli A; Prosperi M; Fadda G; Cauda R; De Luca A
Antivir Ther; 2007; 12(5):835-9. PubMed ID: 17713168
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
[TBL] [Abstract][Full Text] [Related]
17. Genotypic resistance tests for the management of the HIV-infected pregnant woman.
Bassetti D; Cargnel A
Scand J Infect Dis Suppl; 2003; 106():70-4. PubMed ID: 15000589
[TBL] [Abstract][Full Text] [Related]
18. Treatment of antiretroviral-drug-resistant HIV-1 infection.
Deeks SG
Lancet; 2003 Dec; 362(9400):2002-11. PubMed ID: 14683662
[TBL] [Abstract][Full Text] [Related]
19. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral drug resistance and resistance testing.
Gallant JE
Top HIV Med; 2005 Dec-2006 Jan; 13(5):138-42. PubMed ID: 16377851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
